Research Progress of AΒ Targeted Therapy in Clinical Application of Alzheimer's Disease

Shen He

doi:10.62051/5asdfv96

Authors

Shen He

DOI:

https://doi.org/10.62051/5asdfv96

Keywords:

Alzheimer's disease; Aβ; lecanemab.

Abstract

Alzheimer'sdisease (AD) is a progressive neurodegenerative disease that poses a major health challenge to the aging global population. It is characterized by a progressive loss of cognitive functions, including memory, thinking, and behavioral abilities. Current literature shows that there is a critical gap in effective treatment options, as there are no widely accepted treatments that modify disease progression. This gap becomes increasingly important as the prevalence of AD increases. This article analyzes the application of Aβ-targeted therapy in AD, focuses on evaluating the impact of Lecanemab on cognitive function, and comprehensively evaluates the efficacy and safety of the treatment strategy. Study results show that Lecanemab can significantly reduce Aβ plaque burden and improve cognitive function in early-stage AD patients. The significance of this study is to provide a new direction for future AD treatment, and also points out safety issues that still need to be solved in current clinical practice. Future research can focus on improving the biological specificity of monoclonal antibodies and improving the safety of drugs to promote the development of AD treatment.

Downloads

Download data is not yet available.

References

[1] LOGOVINSKY V, SATLIN A, LAI R Y K, et al. Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody [J]. Alz Res Therapy, 2016, 8(1).

[2] SIDDIQI M, MAJID N, MALIK S, et al. Amyloid Oligomers, Protofibrils and Fibrils [J]. Sub-cellular biochem, 2019, 93: 471-503.

[3] ARNSTEN A F T, DATTA D, DEL TREDICI K, BRAAK H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease [J]. Alzheimer's & Dementia, 2021, 17(1): 115-24.

[4] KEPP K P, ROBAKIS N, HøILUND-CARLSEN P, et al. The amyloid cascade hypothesis: an updated critical review [J]. Brain, 2023, 146(10): 3969-90.

[5] ROBINSON S R, BISHOP G M, LEE H-G, MüNCH G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget [J]. Neurobiology of Aging, 2004, 25(5): 609-15.

[6] ZHANG J. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment [J]. Inflamm Res, 2023, 72(9): 1873-6.

[7] KENT S A, SPIRES-JONES T, DURRANT C S. The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics [J]. Acta Neuropathol, 2020, 140(4): 417-47.

[8] ZHANG H, WEI W, ZHAO M, et al. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease [J]. Int J Biol Sci, 2021, 17(9): 2181-92.

[9] LIU Z., LIN Y., HAN A. Aβ oligomers and Alzheimer's disease [J]. Journal of Sun Yat-sen University (Natural Science Edition), 2022, (3): 1-10.

[10] SALLOWAY S, SPERLING R, FOX N C, et al. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease [J]. N Engl J Med, 2014, 370(4): 322-33.

[11] TOLAR M, ABUSHAKRA S, SABBAGH M. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis [J]. Alzheimer's & Dementia, 2019, 16(11): 1553-60.

[12] DYCK C V V, SWANSON C, AISEN P, et al. Lecanemab in Early Alzheimer's Disease [J]. N Engl J Med, 2022, 388(1): 9-21.

[13] CLEARY J, WALSH D, HOFMEISTER J, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function [J]. Nat Neurosci, 2004, 8(1): 79-84.

[14] SEHLIN D, FANG X, CATO L, et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease [J]. Nat Commun, 2016, 7(1).

[15] TOLAR M, ABUSHAKRA S, HEY J A, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval [J]. Alz Res Therapy, 2020, 12(1).

[16] TELI A, DHANDE P. Advancing Alzheimer’s care: a novel therapy with lecanemab [J]. Egypt J Neurol Psychiatry Neurosurg, 2023, 59(1): 1-5.

[17] ABDELAZIM K, ALLAM A A, AFIFI B, et al. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials [J]. Neurol Sci, 2024, 45(8): 3583-97.

[18] HOSSAIN M F, HUSNA A U, KHAREL M. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review [J]. Brain and Behavior, 2024, 14(6).

[19] HONIG L S, SABBAGH M, DYCK C H V, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease [J]. Alz Res Therapy, 2024, 16(1).